PDLIM2 and neoplasm: Furthermore, the suppression of PDLIM2 has been found to reverse the epithelial-to-mesenchymal phenotype and to inhibit tumor growth in vivo, suggesting that targeting these pathways might offer viable therapeutic strategies for TNBC [11].